Skip to search formSkip to main contentSkip to account menu

angiopeptin

Known as: 3-(2-naphthyl)-D-Ala-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2, 3-(2-naphthyl)alanyl-cystinyl-tyrosyl-tryptophyl-lysyl-valyl-cystinyl-threonine amide, D-Nal-Cys-Tyr-Trp-Lys-Val-Cys-Thr-NH2 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
Angiopeptin has been shown to reduce in‐stent restenosis in various animal models. Meanwhile, BiodivYsio DD phosphorylcholine (PC… 
1997
1997
BACKGROUND In-stent restenosis results primarily from neointimal hyperplasia. This study evaluated the efficacy and the optimal… 
Highly Cited
1993
Highly Cited
1993
BackgroundAngiopeptin, a synthetic somatostatin analogue, reduces myointimal hyperplasia after experimental balloon angioplasty… 
1993
1993
Synthetic cyclic octapeptide analogues of somatostatin, such as angiopeptin (BIM23014C; AP) inhibit myointimal proliferation in… 
1993
1993
The effects of the somatostatin analogue, angiopeptin (BIM-23014), on neoendothelial function, as evidenced by formation of… 
1993
1993
1. Currently, a wide range of drugs is being evaluated for the ability to prevent the restenosis which frequently accompanies… 
1992
1992
Extensive smooth muscle cell proliferation is the major event leading to the narrowing or occlusion of the lumen of the coronary…